3 results
the objective of the current study is to evaluate the safety and efficacy of enzyme therapy in the Dutch population of patients with MPS I, II and VI; to compare this to the natural course of these diseases; to make an inventory of the direct and…
Primary: To evaluate the efficacy of FF/UMEC/VI to reduce the annual rate of moderate and severe exacerbations compared with dual therapy of FF/VI or UMEC/VI in subjects with COPD. Secondary: Long term safety and other efficacy parameters.
The primary endpoint is the evaluation of the safety and toxicity of TIL with nivolumab and, thereafter, the safety and toxicity of the combination of PEG-IFNa, nivolumab plus TIL. Safety and toxicity will be evaluated according to CTCAE 4.0…